JP2011529923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529923A5 JP2011529923A5 JP2011521411A JP2011521411A JP2011529923A5 JP 2011529923 A5 JP2011529923 A5 JP 2011529923A5 JP 2011521411 A JP2011521411 A JP 2011521411A JP 2011521411 A JP2011521411 A JP 2011521411A JP 2011529923 A5 JP2011529923 A5 JP 2011529923A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorders
- pharmaceutical
- kit according
- epileptic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008904016 | 2008-08-06 | ||
| AU2008904016A AU2008904016A0 (en) | 2008-08-06 | Treatment for individuals with low dose anti-epileptic drugs or litium-based salts | |
| AU2008904021A AU2008904021A0 (en) | 2008-08-06 | Therapeutic combinations for psychological disorders | |
| AU2008904021 | 2008-08-06 | ||
| PCT/AU2009/001000 WO2010015029A1 (en) | 2008-08-06 | 2009-08-06 | Compositions and methods for treating psychiatric disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529923A JP2011529923A (ja) | 2011-12-15 |
| JP2011529923A5 true JP2011529923A5 (cg-RX-API-DMAC7.html) | 2014-04-10 |
Family
ID=41663218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521411A Pending JP2011529923A (ja) | 2008-08-06 | 2009-08-06 | 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110207718A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2331088A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011529923A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102170874A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009279372A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2732131A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2011001384A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010015029A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US20060159743A1 (en) * | 2001-10-25 | 2006-07-20 | Depomed, Inc. | Methods of treating non-nociceptive pain states with gastric retentive gabapentin |
| US20090176882A1 (en) | 2008-12-09 | 2009-07-09 | Depomed, Inc. | Gastric retentive gabapentin dosage forms and methods for using same |
| US9533938B2 (en) | 2007-01-31 | 2017-01-03 | Biosuccess Biotech Co., Ltd. | Compositions and methods of use of phorbol esters for the treatment of stroke |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| EA033130B1 (ru) | 2008-10-16 | 2019-08-30 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| WO2010094289A1 (en) * | 2009-02-20 | 2010-08-26 | Aarhus Universitet | Allosteric binding compounds |
| ES2758554T3 (es) | 2009-12-08 | 2020-05-05 | Univ Case Western Reserve | Aminoácidos gama para tratamiento de trastornos oculares |
| WO2011143721A1 (en) * | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| BR112013020283A2 (pt) * | 2011-02-09 | 2016-07-19 | Univ Johns Hopkins | "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos" |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| US20140163070A1 (en) * | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US9682073B2 (en) | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US10085414B2 (en) | 2011-05-19 | 2018-10-02 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder speech, gait and limb impairments treatment |
| US9040082B2 (en) * | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
| GB201111712D0 (en) * | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
| EP2804601B1 (en) * | 2012-01-18 | 2025-04-02 | Biosuccess Biotech Co. Ltd. | PHORBOL ESTER compounds for use in the treatment of neoplastic diseases |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| CN103316026B (zh) | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| CN104220064B (zh) * | 2012-03-23 | 2017-10-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种含辛弗林和托吡酯的联合产品 |
| TW201408294A (zh) * | 2012-07-05 | 2014-03-01 | Merz Pharma Gmbh & Co Kgaa | (r)-苯基披喇瑟盪於治療帕金森氏症之用除 |
| EP3663316A1 (en) | 2012-08-21 | 2020-06-10 | Janssen Pharmaceutica NV | Antibodies to aripiprazole and use thereof |
| US9494608B2 (en) | 2012-08-21 | 2016-11-15 | Janssen Pharmaceutica Nv | Antibodies to olanzapine and use thereof |
| CN104736567B (zh) | 2012-08-21 | 2019-09-03 | 詹森药业有限公司 | 阿立哌唑半抗原的抗体及其用途 |
| JP2015529199A (ja) * | 2012-08-21 | 2015-10-05 | オルソ−クリニカル ダイアグノスティクス，インコーポレイティド | パリペリドンハプテンに対する抗体及びその使用 |
| PL3321254T3 (pl) | 2012-08-21 | 2021-01-11 | Janssen Pharmaceutica Nv | Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych |
| PL3462173T3 (pl) | 2012-08-21 | 2021-08-16 | Janssen Pharmaceutica Nv | Przeciwciała przeciwko rysperydonowi i ich zastosowanie |
| ES2733963T3 (es) | 2012-08-21 | 2019-12-03 | Janssen Pharmaceutica Nv | Anticuerpos contra haptenos de olanzapina y uso de los mismos |
| CA2882563C (en) * | 2012-08-21 | 2022-11-29 | Eric Hryhorenko | Antibodies to risperidone haptens and use thereof |
| PT3663317T (pt) | 2012-08-21 | 2023-01-23 | Janssen Pharmaceutica Nv | Anticorpos para haptenos de quetiapina e sua utilização |
| AU2013305907B2 (en) | 2012-08-21 | 2018-01-18 | Saladax Biomedical Inc. | Antibodies to quetiapine and use thereof |
| CN108640996A (zh) | 2012-08-21 | 2018-10-12 | 詹森药业有限公司 | 帕潘立酮的抗体及其用途 |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| EP2970160B1 (en) | 2013-03-15 | 2020-11-11 | Melior Pharmaceuticals II, LLC | Methods of treating dyskinesia and related disorders |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EP2875810A1 (en) * | 2013-11-20 | 2015-05-27 | Biocodex | Pharmacological treatment of obsessive-compulsive disorder using Stiripentol or a similar compound |
| EP2886116A1 (en) * | 2013-12-18 | 2015-06-24 | Biocodex | Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity |
| WO2015098591A1 (ja) * | 2013-12-25 | 2015-07-02 | 株式会社フジモト・コーポレーション | 注意欠如・多動性障害の予防および治療剤 |
| US20170173039A1 (en) * | 2014-04-02 | 2017-06-22 | Yale University | Compositions and methods to treat addiction |
| AU2015280412B2 (en) | 2014-06-26 | 2018-07-26 | Island Breeze Systems Ca, Llc | MDI related products and methods of use |
| GB201416017D0 (en) * | 2014-09-10 | 2014-10-22 | New Royal Holloway & Bedford | An Anticonvulsant Compound |
| EP3201808B1 (en) * | 2014-09-29 | 2021-10-20 | Zogenix International Limited | Control system for control of distribution of medication |
| KR20220071297A (ko) * | 2015-01-28 | 2022-05-31 | 주식회사 제네리스코리아 | 신경정신계 장애의 치료를 위한 조성물 및 방법 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| WO2017007577A1 (en) | 2015-07-08 | 2017-01-12 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
| CN106361734A (zh) * | 2015-07-25 | 2017-02-01 | 云南帕精生物科技有限公司 | 一类治疗精神分裂症药物 |
| EP3349853B1 (en) * | 2015-09-15 | 2023-12-20 | Praxis Bioresearch, LLC | Prodrugs of fencamfamine |
| CN106562945A (zh) * | 2015-10-11 | 2017-04-19 | 云南帕精生物科技有限公司 | 一类治疗帕金森病药物 |
| CN108697662A (zh) * | 2015-12-11 | 2018-10-23 | 奥胡斯大学 | 用于治疗肌强直的卢非酰胺 |
| WO2017106508A1 (en) | 2015-12-17 | 2017-06-22 | Janssen Pharmaceutica Nv | Antibodies to quetiapine and use thereof |
| EP3390449A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica N.V. | Antibodies to risperidone and use thereof |
| CN108883399B (zh) | 2015-12-22 | 2021-06-22 | 周格尼克斯国际有限公司 | 芬氟拉明组合物及其制备方法 |
| US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| CN105456214A (zh) * | 2015-12-30 | 2016-04-06 | 蔡惠文 | 甲磺酸沙芬酰胺片 |
| JP7073272B2 (ja) * | 2016-05-12 | 2022-05-23 | リサーチ トライアングル インスティテュート | 神経伝達物質放出剤としてのビニローグフェネチルアミン |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| CA3062247A1 (en) * | 2017-05-09 | 2018-11-15 | Zogenix International Limited | Methods of treating doose syndrome using fenfluramine |
| US20200360311A1 (en) | 2017-08-03 | 2020-11-19 | Mind Medicine, Inc. | Use of 3-methylmethcathinone |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP4230197A3 (en) * | 2017-10-23 | 2024-01-24 | Cerebral Therapeutics LLC | High concentration medicant solutions for treating neurological disorders |
| SG11202004441XA (en) * | 2017-11-14 | 2020-06-29 | Univ Osaka | Cognitive impairment diagnostic apparatus and cognitive impairment diagnostic program |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| JP7730548B2 (ja) * | 2019-04-18 | 2025-08-28 | プリヴェップ インコーポレイテッド | 治療用組合せ、液状の薬学的組成物、それらの調製のためのキット、およびこれらの使用方法 |
| US12491200B2 (en) | 2019-05-23 | 2025-12-09 | Igc Pharma Ip, Llc | Compositions and methods using cannabinoids for treating stammering/stuttering and symptoms of Tourette syndrome |
| KR20220069014A (ko) | 2019-08-26 | 2022-05-26 | 피리어드 필 비브이 | 월경주기 유도 증후군의 치료 |
| US12014835B2 (en) * | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
| RU2743876C1 (ru) * | 2020-05-19 | 2021-03-01 | Татьяна Евгеньевна Ефремова | Способ реабилитации детей и подростков с поведенческими и эмоциональными нарушениями, страдающих психическими расстройствами |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| CA3204682A1 (en) * | 2020-12-09 | 2022-06-16 | Eysz, Inc. | Systems and methods for monitoring and managing neurological diseases and conditions |
| GB202101462D0 (en) * | 2021-02-03 | 2021-03-17 | Sanchez Hector Mario | Combination therapy for treating executive function disorders |
| US20240197704A1 (en) * | 2021-04-09 | 2024-06-20 | Johns Hopkins University | Treatment methods and compositions comprising perampanel |
| WO2022235530A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
| WO2022265534A1 (ru) * | 2021-06-18 | 2022-12-22 | Гиви Иванович ИКАЕВ | Способ коррекции психического состояния больного шизофренией |
| WO2023281103A1 (en) * | 2021-07-08 | 2023-01-12 | Nls Pharmaceutics Ag | Benedin, piperidine, 2-benzhydryl-3-hydroxy-n-methyl-, hydrochloride and derivatives thereof for use in treating kleine-levin syndrome |
| WO2023107715A1 (en) * | 2021-12-09 | 2023-06-15 | Tactogen Inc | Specialized combinations for mental disorders or mental enhancement |
| US20250375129A1 (en) * | 2022-02-11 | 2025-12-11 | Blinktbi, Inc. | Use of blink reflex for attention-deficit/hyperactivity disorder (adhd) response monitoring and/or treatment selection |
| WO2024123706A1 (en) * | 2022-12-05 | 2024-06-13 | Lykos Therapeutics, Inc. | Compositions comprising mdma and methods of using same |
| CN116831580B (zh) * | 2023-08-31 | 2023-12-01 | 北京中科心研科技有限公司 | 识别抑郁情绪障碍的计算设备应用、装置及可穿戴设备 |
| US12475781B2 (en) | 2023-12-08 | 2025-11-18 | Toyota Motor Engineering & Manufacturing North America, Inc. | Systems and methods for detecting impaired decision-making pedestrians |
| WO2025196662A1 (en) | 2024-03-20 | 2025-09-25 | Clearmind Labs Corp. | Compositions and methods for treating eating disorders |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
| IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
| IT1237904B (it) | 1989-12-14 | 1993-06-18 | Ubaldo Conte | Compresse a rilascio a velocita' controllata delle sostanze attive |
| CA2041774C (en) | 1990-11-27 | 1994-04-19 | Mircea A. Mateescu | Use of cross-linked amylose as a matrix for the slow release of biologically active compounds |
| US5603956A (en) | 1990-11-27 | 1997-02-18 | Labopharm Inc. | Cross-linked enzymatically controlled drug release |
| US5326570A (en) | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| GB9209599D0 (en) | 1992-05-02 | 1992-06-17 | Fisons Corp | Novel therapy for the treatment of parkinsons disease |
| GB9215043D0 (en) | 1992-07-15 | 1992-08-26 | Flow Inc K | Fluid mass flow meters |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
| US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
| US5397574A (en) | 1993-10-04 | 1995-03-14 | Andrx Pharmaceuticals, Inc. | Controlled release potassium dosage form |
| US5399358A (en) | 1993-11-12 | 1995-03-21 | Edward Mendell Co., Inc. | Sustained release formulations for 24 hour release of metroprolol |
| US5419917A (en) | 1994-02-14 | 1995-05-30 | Andrx Pharmaceuticals, Inc. | Controlled release hydrogel formulation |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| US5399359A (en) | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
| DE69535127T2 (de) | 1994-03-18 | 2007-02-15 | Supernus Pharmaceuticals, Inc. | Emulgierte arzneistoffabgabesysteme |
| US5399362A (en) | 1994-04-25 | 1995-03-21 | Edward Mendell Co., Inc. | Once-a-day metoprolol oral dosage form |
| US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| US6103263A (en) | 1994-11-17 | 2000-08-15 | Andrx Pharmaceuticals, Inc. | Delayed pulse release hydrogel matrix tablet |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| JP4863534B2 (ja) | 1996-10-25 | 2012-01-25 | スパーナス ファーマシューティカルズ インコーポレイテッド | 可溶形態浸透用量送達システム |
| US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
| ATE250929T1 (de) | 1997-05-30 | 2003-10-15 | Osmotica Corp | Mehrlagige osmosevorrichtung |
| US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US5916595A (en) | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| US20020102291A1 (en) | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
| US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
| US6106862A (en) | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| US6099862A (en) | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
| EP1600168A3 (en) | 1999-12-01 | 2009-09-23 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder |
| US6417184B1 (en) * | 2000-09-19 | 2002-07-09 | David M. Ockert | Triple drug therapy for the treatment and prevention of acute or chronic pain |
| US8354438B2 (en) * | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| WO2003013514A1 (en) | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| EP1423127A1 (en) * | 2001-08-30 | 2004-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| AU2002340971B2 (en) | 2001-10-08 | 2007-04-26 | Ucb | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders |
| FR2837100B1 (fr) | 2002-03-18 | 2004-07-23 | Flamel Tech Sa | Comprimes a bases de microcapsules a liberation modifiee |
| JP2005534678A (ja) | 2002-06-27 | 2005-11-17 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 注意欠陥多動性障害の治療方法 |
| US7390505B2 (en) * | 2003-01-31 | 2008-06-24 | Elan Pharma International, Ltd. | Nanoparticulate topiramate formulations |
| FR2861990B1 (fr) | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
| EP2036546B1 (en) | 2004-08-23 | 2018-10-10 | PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG | Psychostimulant containing pharmaceutical composition |
| BRPI0520258A2 (pt) * | 2005-05-06 | 2009-09-15 | Portela & Ca Sa | uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina |
| DE102006015734A1 (de) * | 2006-04-04 | 2007-10-11 | Hermann, Holger Lars, Dr. | Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung |
| US8679540B2 (en) | 2006-06-09 | 2014-03-25 | Flamel Technologies | Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications |
| ES2547226T5 (es) | 2006-08-30 | 2020-06-12 | Jagotec Ag | Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| AU2008279636A1 (en) * | 2007-07-25 | 2009-01-29 | The Regents Of The University Of Colorado | Central administration of stable formulations of therapeutic agents for CNS conditions |
| US20110065628A1 (en) * | 2007-08-27 | 2011-03-17 | University Of Virginia Patent Foundation | Medication Combinations for the Treatment of Alcoholism and Drug Addiction |
| AU2009246847A1 (en) | 2008-05-14 | 2009-11-19 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
| EA037187B1 (ru) | 2010-02-09 | 2021-02-17 | Дзе Джонс Хопкинс Юниверсити | Способ и композиция для лечения когнитивного расстройства |
| WO2011143721A1 (en) | 2010-05-21 | 2011-11-24 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating neurodegenerative disorders |
-
2009
- 2009-08-06 MX MX2011001384A patent/MX2011001384A/es not_active Application Discontinuation
- 2009-08-06 WO PCT/AU2009/001000 patent/WO2010015029A1/en not_active Ceased
- 2009-08-06 CA CA2732131A patent/CA2732131A1/en not_active Abandoned
- 2009-08-06 EP EP09804384A patent/EP2331088A4/en not_active Withdrawn
- 2009-08-06 AU AU2009279372A patent/AU2009279372A1/en not_active Abandoned
- 2009-08-06 JP JP2011521411A patent/JP2011529923A/ja active Pending
- 2009-08-06 CN CN2009801390755A patent/CN102170874A/zh active Pending
- 2009-08-06 US US13/057,628 patent/US20110207718A1/en not_active Abandoned
-
2015
- 2015-04-06 US US14/679,559 patent/US10028971B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529923A5 (cg-RX-API-DMAC7.html) | ||
| EP2592066B1 (en) | Aminocarboxylic acid derivative and medical use thereof | |
| SK2262002A3 (en) | Composition comprising a tramadol material and an anticonvulsant drug | |
| JP2012505238A5 (cg-RX-API-DMAC7.html) | ||
| JP2008521827A5 (cg-RX-API-DMAC7.html) | ||
| TW200814988A (en) | Therapeutic combination for painful medical conditions | |
| AU2002340971B2 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders | |
| JP2017505786A (ja) | 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用 | |
| JP2002539256A (ja) | 一定の親和性のあるｎｍｄａアンタゴニストの抗うつ剤としての使用 | |
| JP2006520761A (ja) | 薬物誘発性細胞毒性の予防のための化合物の使用 | |
| US20050124701A1 (en) | Method of targeting a therapeutic agent | |
| JP2025163212A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| US20060223884A1 (en) | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | |
| JP5386478B2 (ja) | パーキンソン病に伴う運動不全の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| JP2002541077A (ja) | Ｎｏ合成酵素阻害剤と代謝酸化防止剤の組み合わせ | |
| EP1734940B1 (en) | Combinations of deramciclane and opioids for use as analgesics | |
| JP5163986B2 (ja) | フェニル酪酸ナトリウムを使用する、薬物依存症又はアルコール依存症或いは躁うつ病の予防又は治療のための医薬組成物 | |
| EP4582412A1 (en) | Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor | |
| RU2433121C2 (ru) | Производное аминокарбоновой кислоты и применение указанного вещества в медицинских целях | |
| WO2025231265A1 (en) | Combination with alpha-2 adrenergic receptor agonist | |
| AU2017263457B2 (en) | Vinylogous phenethylamines as neurotransmitter releasers | |
| AU766708B2 (en) | The treatment of renal colic with GABA analogs | |
| JP2007509865A (ja) | 神経障害の治療における選択的オピエート受容体調節物質の使用 | |
| RU2007136824A (ru) | Пролекарства амфетаминов с защитой от неправильного употребления | |
| RU99125616A (ru) | Соединения |